Table 1 Patient and tumour characteristics at time of brain metastases diagnosis
From: Temporal evolution of breast cancer brain metastases treatments and outcomes
Group A (2000–2007) N = 241 (%) | Group B (2008–2014) N = 323 (%) | Group C (2015–2022) N = 215 (%) | p value | |
|---|---|---|---|---|
Age at BMs diagnosis | ||||
≤50 years | 96 (39.8) | 104 (32.2) | 83 (38.6) | 0.126 |
>50 years | 145 (60.2) | 219 (67.8) | 132 (61.4) | |
Tumour histology | ||||
No special type | 199 (82.6) | 274 (84.8) | 171 (79.5) | 0.562 |
Other | 42 (17.4) | 49 (15.2) | 39 (18.2) | |
Missing | 0 (0.0) | 0 (0.0) | 5 (2.3) | |
Histological grade | ||||
G1-G2 | 96 (39.8) | 119 (36.8) | 56 (26.0) | 0.018 |
G3 | 127 (52.7) | 183 (56.7) | 132 (61.4) | |
Missing | 18 (7.5) | 21 (6.5) | 27 (12.6) | |
HR status | ||||
Positive | 120 (49.8) | 177 (54.8) | 136 (63.2) | 0.012 |
Negative | 121 (50.2) | 146 (45.2) | 78 (36.3) | |
Missing | 0 (0.0) | 0 (0.0) | 1 (0.5) | |
HER2 status | ||||
Positive | 105 (43.6) | 141 (43.7) | 86 (40.0) | 0.598 |
Negative | 129 (53.5) | 180 (55.7) | 127 (59.1) | |
Missing | 7 (2.9) | 2 (0.6) | 2 (0.9) | |
Subtypes | ||||
HR+/HER2- | 72 (29.9) | 103 (31.9) | 82 (38.1) | 0.032 |
HR+/HER2+ | 40 (16.6) | 70 (21.7) | 53 (24.7) | |
HR-/HER2+ | 65 (27.0) | 71 (22.0) | 33 (15.4) | |
HR-/HER2- | 57 (23.6) | 77 (23.8) | 45 (20.9) | |
Missing | 7 (2.9) | 2 (0.6) | 2 (0.9) | |
Stage at BC diagnosis | ||||
I-III | 201 (83.4) | 255 (78.9) | 154 (71.6) | 0.009 |
IV | 40 (16.6) | 68 (21.1) | 61 (28.4) | |
Distant metastases free survival, months (95% CI)* | 26.3 (21.5-31.0) | 31.4 (25.8-37.0) | 25.8 (21.2-30.5) | 0.163 |
BMs free survival, months (95% CI)* | 9.5 (7.1-11.9) | 11.7 (9.5-13.9) | 12.7 (8.4-17.0) | 0.002 |
KPS at BMs diagnosis | ||||
90-100 | 54 (22.4) | 60 (18.6) | 63 (29.3) | 0.007 |
70-80 | 121 (50.2) | 141 (43.7) | 82 (38.1) | |
≤60 | 66 (27.4) | 98 (30.3) | 43 (20.0) | |
Missing | 0 (0.0) | 24 (7.4) | 27 (12.6) | |
BMs at first metastatic BC diagnosis | ||||
Yes | 70 (29.0) | 80 (24.8) | 57 (26.5) | 0.523 |
No | 171 (71.0) | 243 (75.2) | 158 (73.5) | |
Number of BMs | ||||
1 | 49 (20.3) | 90 (27.9) | 72 (33.5) | 0.084 |
2 | 39 (16.2) | 42 (13.0) | 30 (13.9) | |
3 | 20 (8.3) | 21 (6.5) | 15 (7.0) | |
≥4 | 133 (55.2) | 169 (52.3) | 98 (45.6) | |
Missing | 0 (0.0) | 1 (0.3) | 0 (0.0) | |
Extracranial metastases | ||||
Absent | 26 (10.8) | 33 (10.2) | 27 (12.6) | 0.652 |
Present | 215 (89.2) | 290 (89.8) | 185 (86.0) | |
Missing | 0 (0.0) | 0 (0.0) | 3 (1.4) | |
Leptomeningeal disease at BMs diagnosis | ||||
Yes | 4 (1.7) | 23 (7.1) | 31 (14.4) | <0.001 |
No | 237 (98.3) | 300 (92.9) | 184 (85.6) |
